This study examines the clinical, pathological, immunohistochemical, and genetic profiles of 36 patients with advanced SMARCA4‐deficient thoracic tumors, focusing on their responses to chemotherapy and immunotherapy. Here, SMARCA4 is linked to neoplasm of thorax.